Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism STING agonists(Stimulator of interferon genes agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H22F2N10O9P2S2 |
InChIKeyYSUIQYOGTINQIN-DGVVHPOBSA-N |
CAS Registry2082743-96-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | KR | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | GB | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | FR | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | US | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | BR | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | AT | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | ES | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | AU | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | NO | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | IL | 04 Mar 2020 |
Phase 1 | 156 | (Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions)) | fpcqpovorw(rizchfqzwf) = yyphhgkcvb wpjmwbtmxr (ulrexdqigh, rnyqjnrzmo - utcfzjcfpz) View more | - | 26 Feb 2024 | ||
(Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions)) | fpcqpovorw(rizchfqzwf) = dexmmsinyj wpjmwbtmxr (ulrexdqigh, mvsaavaxvx - jtgwmbvsju) View more | ||||||
Phase 1 | 51 | (hkmaffxoaj) = qcnduyntki jsgbessnoy (dqugrucwzn ) View more | Positive | 20 Oct 2018 | |||
(hkmaffxoaj) = grgdumsjmp jsgbessnoy (dqugrucwzn ) View more | |||||||
Phase 1 | 157 | rhcndflztc(ciztbrtztz) = resulted in discontinuation of 7% of pts in Arm 2 (0% in Arm 1) ynqsrfcejp (vgscalgvrd ) View more | Positive | 20 Oct 2018 | |||